💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Donepezil

CHEMBL502 Phase 4 Zugelassen Small molecule
Half-Life
70 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
379.5 g/mol
LogP
4.3
Phase
4

An acetylcholinesterase inhibitor used to treat symptoms of Alzheimer's disease by increasing levels of acetylcholine, a brain chemical important for memory and cognition. It helps improve or stabilize cognitive function in affected patients.

Molekularmasse

379,4920 g/mol

LogP

4,30

TPSA

38,80 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Infectious Disease Oncology Gastroesophageal Reflux Disease Inflammatory Bowel Disease Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Hypertension Breast Cancer Prostate Cancer Colorectal Cancer

Arzneimittelklassen

N — N - Nervous System

Wirkmechanismus

Reversible acetylcholinesterase inhibitor.

Pharmacokinetics (PK)

Half-Life 70 hours

Pharmacodynamics (PD)

Mechanismus

Reversible acetylcholinesterase inhibitor.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2

                

                

                
                

                    
InChI

                    
InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H29NO3

                    

                    
                    

                        
HBD / HBA

                        
- / 4

                    

                    
                    

                        
Rotierbare Bindungen

                        
6

                    

                    
                    
                    

                        
Schwere Atome

                        
28

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            ABCB1 (P-glycoprotein)
                            Substrate
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            SIGMAR1 (Sigma-1 Receptor)
                            Binder
                        

                        
                    

                    
                    

                        

                            CYP3A4 (Cytochrome P450 3A4)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Donepezil + Quetiapine
                            
                        

                        
                        
Quetiapine's anticholinergic properties antagonize the pro-cholinergic mechanism of donepezil, potentially impairing cognitive benefits in dementia.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Donepezil + Diphenhydramine
                            
                        

                        
                        
Diphenhydramine's potent anticholinergic effect directly opposes donepezil's pro-cholinergic mechanism, negating therapeutic benefit and increasing risk of delirium in elderly patients.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
An acetylcholinesterase inhibitor used to treat symptoms of Alzheimer's disease by increasing levels of acetylcholine, a brain chemical important for memory and cognition. It helps improve or stabilize cognitive function in affected patients.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Reversible acetylcholinesterase inhibitor.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Donepezil: Half-life: 70 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Donepezil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL502.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3152.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.